Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.56 |
| ▸ | GSK3B | P49841 | 5/20 | 0.56 |
| ▸ | WNT1 | P04628 | 2/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.47 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.47 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979420 | 0.90 | F10 (0.61) | F10DYRK1AGSK3BWNT1FLT3 | |
| SCHEMBL23635141 | 0.88 | F10 (0.49) | F10DYRK1AGSK3BWNT1MAPK14 | |
| SCHEMBL18979422 | 0.88 | F10 (0.62) | F10DYRK1AGSK3BWNT1FLT3 | |
| SCHEMBL18979456 | 0.86 | F10 (0.61) | F10DYRK1AGSK3BWNT1FLT3 | |
| SCHEMBL4251772 | 0.77 | EPHX2 (0.73) | F10DYRK1AGSK3BWNT1MAPK14 | |
| SCHEMBL31672283 | 0.77 | DEGS1 (0.68) | ABCB1ABCC1SMN1; SMN2DEGS1 | |
| SCHEMBL17040257 | 0.77 | DEGS1 (0.68) | ABCB1ABCC1SMN1; SMN2DEGS1 | |
| SCHEMBL18979436 | 0.76 | SMN1; SMN2 (0.54) | DYRK1AGSK3BABCB1ABCC1SMN1; SMN2 | |
| SCHEMBL18979462 | 0.75 | SMN1; SMN2 (0.52) | DYRK1AGSK3BABCB1ABCC1SMN1; SMN2 | |
| SCHEMBL18979454 | 0.74 | ABCB1 (0.53) | DYRK1AGSK3BWNT1ABCB1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | FROST BIOLOGIC, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | FROST BIOLOGIC, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | F10 4190/4885DYRK1A 1592/4885GSK3B 2689/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | F10 2263/4885DYRK1A 1713/4885GSK3B 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.